Description:
This is a phase 2 study. The goal of this study is to find out what effects, good and/or bad,
taking erlotinib and ruxolitinib has on the patients and on lung cancer. Erlotinib and
ruxolitinib are FDA approved for other indications, but the use of erlotinib and ruxolitinib
together has not been studied before and is not FDA-approved.
Title
- Brief Title: Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
- Official Title: A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Clinical Trial IDs
- ORG STUDY ID:
14-043
- NCT ID:
NCT02155465
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Ruxolitinib | | Ruxolitinib and Erlotinib |
Erlotinib | | Ruxolitinib and Erlotinib |
Purpose
This is a phase 2 study. The goal of this study is to find out what effects, good and/or bad,
taking erlotinib and ruxolitinib has on the patients and on lung cancer. Erlotinib and
ruxolitinib are FDA approved for other indications, but the use of erlotinib and ruxolitinib
together has not been studied before and is not FDA-approved.
Trial Arms
Name | Type | Description | Interventions |
---|
Ruxolitinib and Erlotinib | Experimental | Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.
Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily. | |
Eligibility Criteria
Inclusion Criteria:
- Pathologic evidence of advanced (non-operable or metastatic) biopsy-proven stage IV or
recurrent lung cancer reviewed at MSKCC.
- a documented somatic activating mutation in EGFR (including but not limited to Exon 19
deletion or L858R)
- Radiographic progression during treatment with erlotinib. Prior chemotherapy regimens
are permitted.
- Received erlotinib or other EGFR TK treatment for at least 2 weeks prior to enrollment
- Measurable (RECIST 1.1) indicator lesion not previously irradiated
- Must have undergone biopsy after development of acquired resistance to erlotinib
(which is performed as standard of care) with adequate tissue to determine EGFR T790M
and tumor histology. Slides from an outside institution may be used.
- KPS ≥ 70%
- Age>18 years old
- Patients must have adequate organ function:
- AST, ALT, Alk phos ≤ 3.0 x ULN
- Total bilirubin ≤ 2.0 x ULN
- Creatinine <2.0 X upper limit of normal and/or a creatinine clearance ≥ 60ml/min
- Absolute neutrophil count (ANC) ≥1,000 cells/mm³.
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9.0g/dL.
Exclusion Criteria:
- Concurrent therapy with a potent CYP3A4 inducer or inhibitor. Subjects may enter
screening when therapy with the potent inhibitor or inducer is completed and may begin
study treatment after 1 week or 5 half-lives, whichever is longer.
- Patients with symptomatic brain metastasis requiring escalating doses of steroids.
- Any type of systemic therapy (chemotherapy or experimental drugs) within 3 weeks of
starting treatment on protocol except for erlotinib or other EGFR TKI.
- Any radiation within 2 weeks prior to starting treatment on protocol
- Patients with ≥ grade 2 or greater diarrhea despite maximal medical management due to
medications or a medical condition such as Crohn's disease, malabsorption.
- Inadequate recovery from any toxicities related to prior treatment (to Grade 1 or
baseline).
- Pregnant or lactating women
- Patients who have received prior treatment with JAK inhibitor
- Previously or current malignancies at other sites within the last 2 years, with the
exception of adequately treated in situ carcinoma of the cervix, basal or squamous
cell carcinoma of the skin, prostate cancer that does not require active treatment per
National Comprehensive Cancer Network (NCCN) guidelines, superficial bladder cancer or
other noninvasive indolent or stage 1 malignancy without sponsor approval.
- Clinically significant cardiac disease including unstable angina, acute myocardial
infarction within 6 months from Day 1 of study drug administration, New York Heart
Association Class III or IV congestive heart failure, or symptomatic arrythmias
requiring therapy,
- Chronic or current active infections requiring systemic antibiotics, antifungals or
antiviral therapy.
- Known human immunodeficiency virus infection, or hepatitis B virus (HBV) viremia or
hepatitis C virus (HCV) viremia. Screening for the study does not require assessment
for these infections if not already known.
- Any other condition that, in the opinion of the Investigator, may compromise the
safety, compliance of the patient, or would preclude the patient from successful
completion of the study.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 19 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Maximally Tolerated Dose (MTD) (Phase I) |
Time Frame: | 1 year |
Safety Issue: | |
Description: | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD), at least a 20% increase in the sum of the diameter of the target lesions or the appearance of one or more new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD |
Secondary Outcome Measures
Measure: | Number of Participants With NCI CTCAE Toxicity |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Toxicity grading will be performed in accordance with NCI CTCAE, version 4.0. |
Measure: | Progression-free Survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
Trial Keywords
- Ruxolitinib
- Erlotinib
- EGFR-mutant
- 14-043
Last Updated
January 16, 2019